US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cabela's

61.50

0.0000

Volume:- -

Turnover:- -

Market Cap:4.24B

PE:28.87

High:61.50

Open:61.50

Low:61.50

Close:61.50

52wk High:63.60

52wk Low:45.00

Shares:68.91M

Float Shares:50.99M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):2.13

ROE:--

ROA:--

PB:2.04

PE(LYR):- -

Loading ...

Overview Company News Filings

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

CAB Payments Shares Fall After Warning on International Developmental Organization Volumes

CAB Payments Receives $480 Million Takeover Proposal From StoneX

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

CAB Payments' Pretax Profit Falls on Lower Volumes, Full-Year Guidance Confirmed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CAB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CAB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAB\",,,,,undefined,":{"symbol":"CAB","market":"US","secType":"STK","nameCN":"Cabela's","latestPrice":61.5,"timestamp":1575666000000,"preClose":61.5,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":50994952,"shares":68912000,"eps":2.13,"marketStatus":"Delisted","change":0,"latestTime":"05-13 11:54:25 EDT","open":61.5,"high":61.5,"low":61.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":61.5,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAB\",,,,,undefined,":{"symbol":"CAB","floatShares":50994952,"roa":"--","roe":"--","lyrEps":0,"shares":68912000,"dividePrice":0,"high":61.5,"amplitude":0,"preClose":61.5,"low":61.5,"week52Low":45,"pbRate":"2.04","week52High":63.6011,"institutionHeld":0.8483,"latestPrice":61.5,"eps":2.13,"divideRate":0,"volume":0,"delay":0,"ttmEps":2.13,"open":61.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CAB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-08-03","symbol":"CAB","fiscalQuarterEnding":"2017/06","expectedEps":0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"pre","actualEps":0.53},{"market":"US","date":"2017-05-04","symbol":"CAB","fiscalQuarterEnding":"2017/03","expectedEps":0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1493870400000,"reportTimeType":"pre","actualEps":0.4},{"market":"US","date":"2017-02-16","symbol":"CAB","fiscalQuarterEnding":"2016/12","expectedEps":1.22,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1487221200000,"reportTimeType":"pre","actualEps":1.05},{"market":"US","date":"2016-10-26","symbol":"CAB","fiscalQuarterEnding":"2016/09","expectedEps":0.8,"name":null,"time":"","type":"earning","dateTimestamp":1477454400000,"reportTimeType":"","actualEps":0.53},{"market":"US","date":"2016-07-28","symbol":"CAB","fiscalQuarterEnding":"2016/06","expectedEps":0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1469678400000,"reportTimeType":"pre","actualEps":0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CAB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CAB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CAB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2480021304","title":"Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2480021304","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480021304?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:25","pubTimestamp":1730723100,"startTime":"0","endTime":"0","summary":"-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2973936/0/en/Korro-Announces-Regulatory-Filing-for-Initiation-of-KRRO-110-First-In-Human-Study-and-Formation-of-Clinical-Advisory-Board.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","CAB","TGA","BK4139","BK4585","RNA","BK4588","BK4505","KRRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2479083923","title":"BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479083923","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479083923?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  31, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2972560/0/en/BioAtla-to-Announce-Third-Quarter-2024-Financial-Results-and-Provide-Business-Highlights-on-November-7-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAB","CAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2479722291","title":"CAB Payments Shares Fall After Warning on International Developmental Organization Volumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2479722291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479722291?lang=en_us&edition=fundamental","pubTime":"2024-10-30 16:51","pubTimestamp":1730278260,"startTime":"0","endTime":"0","summary":"CAB Payments Holdings shares fell after the company posted lower-than-expected revenue for the third quarter and warned that it anticipates a sharp decline in volumes from international developmental organizations in the remainder of the year.In early trading, London-listed shares were down 7%, at 112.60 pence. Year-to-date, shares have risen 34%.The fintech group, which specializes in cross-border payments, said Wednesday that revenue for the period was in line with its expectations for July and August, but marginally below its expectations by the end of September.The company previously expected that volumes would increase in the fourth quarter due to the usual seasonality, despite reduced international developmental organization client budgets. However, it now expects that this volume increase is unlikely to materialize due to a challenging environment and political factors.In the nine months to Sept. 30, the group's foreign-exchange and payments volumes grew 9% on a combined basis, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2474589729","title":"CAB Payments Receives $480 Million Takeover Proposal From StoneX","url":"https://stock-news.laohu8.com/highlight/detail?id=2474589729","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474589729?lang=en_us&edition=fundamental","pubTime":"2024-10-11 00:29","pubTimestamp":1728577740,"startTime":"0","endTime":"0","summary":"U.K.-listed CAB Payments said it received an unsolicited takeover proposal from U.S. listed StoneX that values the fintech group at nearly $500 million.CAB Payments said Thursday that the proposal for 145 pence per share in cash, together with a full share alternative, was received on Sept. 23 and follows a series of approaches from StoneX since late July. StoneX's first proposal valued CAB Payments at 115 pence per share, the company said.The revised offer represent a nearly 18% premium to CAB Payment's share price of 123 pence at Thursday's market close, valuing the group at 368.50 million pounds .After rejecting the initial proposal, CAB Payments said it is evaluating the revised offer and StoneX now has until 1700 GMT on Nov. 7 to announce a firm intention to make an offer under U.K takeover law.CAB Payments listed on the London Stock Exchange in July 2023 and has since seen its share price tumble more than half.StoneX Group is listed on Nasdaq and offers payments, risk management ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAB","BK4127","SNEX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2472930951","title":"BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2472930951","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472930951?lang=en_us&edition=fundamental","pubTime":"2024-10-04 21:05","pubTimestamp":1728047100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  04, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/04/2958357/0/en/BioAtla-Announces-Upcoming-Poster-Presentation-at-the-39th-Society-for-Immunotherapy-of-Cancer-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","SITC","CAB","BCAB","BK4231","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2472321298","title":"BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2472321298","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472321298?lang=en_us&edition=fundamental","pubTime":"2024-10-01 20:00","pubTimestamp":1727784000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  01, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/01/2956027/0/en/BioAtla-Announces-Upcoming-Oral-Presentation-at-the-Society-for-Melanoma-Research-21st-International-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMR","BK4139","CAB","BCAB","BK4182"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2466916975","title":"BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2466916975","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466916975?lang=en_us&edition=fundamental","pubTime":"2024-09-09 20:00","pubTimestamp":1725883200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/09/2942777/0/en/BioAtla-Announces-Upcoming-Poster-Presentation-at-the-2024-European-Society-for-Medical-Oncology-ESMO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAB","BK4139","BCAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2464345073","title":"CAB Payments' Pretax Profit Falls on Lower Volumes, Full-Year Guidance Confirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2464345073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464345073?lang=en_us&edition=fundamental","pubTime":"2024-09-04 15:04","pubTimestamp":1725433440,"startTime":"0","endTime":"0","summary":"CAB Payments Holdings' pretax profit and gross income fell as global demand for foreign-exchange services dropped and the tailwinds that drove last year's performance fade, but the company confirmed its full-year guidance.The fintech group on Wednesday posted pretax profit for the six months ended June 30 of 13.7 million pounds , down 43% from the same period a year prior.Gross income fell to 55.7 million pounds from 71.8 million pounds, while adjusted earnings before interest, taxes, depreciation and amortization fell to 18.7 million pounds, down from 40.0 million pounds, due to lower revenue and higher operating expenses, the company said.The company estimates that there has been a 10% year-on-year drop in global cross-border flows and an around 5% drop in flows into Africa due to the strong dollar and global political volatility. However, it expects demand for foreign-exchange flows and payments to grow over the long-term.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}